« Previous
Next »
Leukemia Research
Volume 33, Issue 9
, Pages
1183-1188
, September 2009
Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes
To access this article, please choose from the options below
PII: S0145-2126(09)00154-4
doi: 10.1016/j.leukres.2009.03.027
© 2009 Elsevier Ltd. All rights reserved.
« Previous
Next »
Leukemia Research
Volume 33, Issue 9
, Pages
1183-1188
, September 2009
